★★★★★
This recent human study suggests that melatonin may be useful in improving the quality of life (QOL), oxidative stress and cardiovascular function of people with PAH as discussed here :
https://pmc.ncbi.nlm.nih.gov/articles/PMC12177658/
Here are some relevant quotes from the full study link :
' Overall, oral melatonin treatment improved the plasma antioxidant capacity and the QoL in this pilot study. '
' A significant improvement was noticed in perception of dyspnea, palpitations, and fatigue in concordance with the QoL improvement in the physical domain after 6 months of melatonin. This was represented by a significant fall in the total score of the PAH-SYMPACT questionnaire. In addition, the baseline heart rate was lower at the T6 follow-up. '
' Another important finding of our study is the improved physical domain of the SYMPACT PAH questionnaire, which is in concordance with symptomatic improvement. This is relevant because it favors patients treatment adherence and QoL [53]. Even more, having a better physical perception, patients tend to improve their confidence to perform more activities. '
It is interesting to note that this study used a fairly low dose of melatonin at just 6 mg per day and reported benefit at 3 months and further benefit at 6 months of dosing . Other human studies have used 10 to 50 mg or more per day of melatonin for various health issues. No significant side effects were reported in this study. Melatonin has also shown to have a very good safety profile. It would have been interesting to see an even longer study duration, a higher dosing arm or both.
Art
